Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.
Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. Bekker LG, et al. Among authors: vella s. Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Lancet. 2018. PMID: 30032975 Free PMC article. Review. No abstract available.
In memoriam: Joep Lange MD, PhD.
Beyrer C, Vella S, Cooper DA. Beyrer C, et al. Among authors: vella s. J Int AIDS Soc. 2014 Sep 8;17(1):19401. doi: 10.7448/IAS.17.1.19401. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25204873 Free PMC article. No abstract available.
Maximizing the benefits of antiretroviral therapy for key affected populations.
Grubb IR, Beckham SW, Kazatchkine M, Thomas RM, Albers ER, Cabral M, Lange J, Vella S, Kurian M, Beyrer C; IAS Treatment for Key Affected Populations Working Group. Grubb IR, et al. Among authors: vella s. J Int AIDS Soc. 2014 Jul 18;17(1):19320. doi: 10.7448/IAS.17.1.19320. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25043380 Free PMC article.
Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.
George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group. George EC, et al. Among authors: vella s. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844. J Acquir Immune Defic Syndr. 2018. PMID: 30234665 Free PMC article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Among authors: vella s. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Time to act: global apathy towards HIV/AIDS is a crime against humanity.
Hogg R, Cahn P, Katabira ET, Lange J, Samuel NM, O'Shaughnessy M, Vella S, Wainberg MA, Montaner J. Hogg R, et al. Among authors: vella s. Lancet. 2002 Nov 30;360(9347):1710-1. doi: 10.1016/s0140-6736(02)11722-3. Lancet. 2002. PMID: 12480418 No abstract available.
591 results